Scarica l'app Stockscreener
0.5924
4.85%
-0.0302
Dopo l'orario di chiusura:
.59
-0.0024
-0.41%
Precedente Chiudi:
$0.6226
Aprire:
$0.6189
Volume 24 ore:
1.40M
Relative Volume:
0.43
Capitalizzazione di mercato:
$95.86M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
14.81
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
+0.58%
1M Prestazione:
-38.96%
6M Prestazione:
-83.86%
1 anno Prestazione:
-89.93%
Intervallo 1D:
$0.5805
$0.6277
Intervallo di 1 settimana:
$0.55
$0.67
Portata 52W:
$0.5271
$7.105
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Confronta IRWD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.5924 | 95.31M | 400.57M | 9.21M | 146.36M | 0.04 |
|
HLN
Haleon Plc Adr
|
11.25 | 49.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
165.40 | 71.87B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.80 | 4.35M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.59 | 44.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.15 | 18.98B | 16.54B | -1.64B | 749.00M | -1.45 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $4.78 - Defense World
Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Pacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Ironwood: Q1 Earnings Snapshot - New Haven Register
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook By Investing.com - Investing.com India
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook - Investing.com
Ironwood Pharmaceuticals (IRWD) Maintains LINZESS Sales Outlook Amid Pricing Challenges | IRWD Stock News - GuruFocus
Ironwood (IRWD) Reports Q1 Revenue Shortfall, Ending Quarter with Increased Cash Reserves | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Ironwood Pharmaceuticals Q1 2025 Earnings: EPS of -$0.23 Misses Estimate, Revenue Falls Short at $41.14 Million - GuruFocus
Ironwood Pharmaceuticals Reports First Quarter 2025 Results | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals Reports First Quarter 2025 Results - Business Wire
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo
Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView
Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):